TI
PVLA

Truepoint Inc’s Palvella Therapeutics PVLA Stock Holding History

Truepoint Inc’s Portfolio PVLA Stock Details PVLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-125
Closed -$30K – 173
2022
Q1 		$30K Hold
125
– – ﹤0.01% 137
2021
Q4 		$38K Hold
125
– – ﹤0.01% 135
2021
Q3 		$52K Buy
+125
New +$43.5K ﹤0.01% 129

Other funds holding PVLA

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
ACM
Aquilo Capital Management San Francisco, California $55.8M AUM 41.76% 1-Year Est. Return
LCM
Lynx1 Capital Management San Juan, Puerto Rico $633M AUM 173.22% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Truepoint Inc's PVLA Position: Q2 2022 in Review

Truepoint Inc sold out of Palvella Therapeutics (PVLA) in Q2 2022, closing a stake of 125 shares — an estimated $30K sold.

Truepoint Inc first reported a position in PVLA in Q3 2021 and held it in 3 quarters. The position peaked at $52K in Q3 2021. 68 funds tracked by Wall St. Rank hold PVLA as of Q2 2022.

  • Truepoint Inc reported no remaining Palvella Therapeutics position as of Q2 2022 after selling out during the quarter.
  • Truepoint Inc sold 125 Palvella Therapeutics shares in Q2 2022, an estimated $30K.
  • Truepoint Inc first reported a position in Palvella Therapeutics in Q3 2021 and held it in 3 quarters.
  • Truepoint Inc's Palvella Therapeutics position peaked at $52K in Q3 2021.
  • 68 funds tracked by Wall St. Rank held Palvella Therapeutics as of Q2 2022.

Based on Truepoint Inc's 13F filing for Q2 2022, filed 8 Aug 2022.